Editas Medicine, Inc.
EDITHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. With a market capitalization of $496.1M, it sits in small-cap territory. The company develops a proprietary gene editing platform based on CRISPR technology.
Market Cap
$496.1M
Beta
2.09
P/E (TTM)
—
P/E (Fwd)
-4.29
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.75
ROE
-118.8%
ROA
-23.3%
Cash
$211.6M
Total Debt
$15.5M
Free CF
-$44.3M
52W Change
17.0%
Annual Financials
Cash vs Debt
Where EDIT stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, EDIT finished 22.64% above its 150-day moving average ($2.65) and 25.48% above its 200-day moving average ($2.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EDIT overbought or oversold?
At the August 20, 2026 close, EDIT's RSI(14) was 71.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $211.6M in cash comfortably exceeding the $15.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$44.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -118.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $19.7M (2022) to $40.5M (2025), reflecting a 106% increase over the period.
With a beta above 1.5, EDIT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, EDIT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Editas Medicine, Inc.'s trajectory.